-
2 days ago | 
bioworld.com | Nuala Moran
Home » EMA: New clinical guideline includes pregnant, breastfeeding patients BioWorld briefs for June 5, 2025. BioWorld MedTech briefs for June 4, 2025. The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its... BioWorld Asia briefs for June 3, 2025 It’s a good week to be working on drugs targeting STAT6.
-
3 days ago | 
bioworld.com | Nuala Moran
Pharma execs speak out: UK pricing rebates scare investorsThe row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its members to speak on the record, as it ramps up the campaign against paying back over 23% on sales of branded drugs. BioWorld Regulatory Europe
-
4 days ago | 
bioworld.com | Nuala Moran
Atai in $370M merger deal with psychedelic drug specialist Beckley Privately held Beckley Psytech Ltd. is to be taken over by Atai Life Sciences in an all-share deal that values the U.K. psychedelic drug specialist at $370 million. After making a $50 million investment in January 2024, Berlin-based Atai already owns 36% of Beckley. It will now issue 105 million new shares to its fellow Beckley investors, giving them 34% ownership of the merged company.
-
5 days ago | 
bioworld.com | Nuala Moran
Sanofi buying Blueprint and its TKI BLU-808 for $9.5BSanofi SA is to acquire Blueprint Medicines Inc. in a $9.5 billion deal that will give the French pharma ownership of a marketed rare disease immunotherapy heading toward blockbuster status, a follow-on product in phase II/III, and a phase II clinical program relevant to a number of autoimmune diseases. BioWorld Deals and M&A Immune Small molecule Europe U.S.
-
1 week ago | 
bioworld.com | Nuala Moran
EU launches new strategy supporting growth of innovative startupsThe EU is having another go at improving access to capital for biotechs and science-based startups, in a bid to enable them to remain anchored in Europe.
-
1 week ago | 
bioworld.com | Nuala Moran
More mutations than previously thought in childhood cancersResearchers in the U.K. have overthrown the orthodox view that childhood cancers have a low mutation burden, opening up new drug targets and opportunities for repurposing existing therapies. In particular, a high mutation rate is associated with a response to cancer immunotherapy.
-
1 week ago | 
bioworld.com | Nuala Moran
More mutations than previously thought in childhood cancersResearchers in the U.K. have overthrown the orthodox view that childhood cancers have a low mutation burden, opening up new drug targets and opportunities for repurposing existing therapies. In particular, a high mutation rate is associated with a response to cancer immunotherapy.
-
1 week ago | 
bioworld.com | Nuala Moran
Home » Glycoera raises a $130M series B to advance GE-8820 BioWorld briefs for May 28, 2025. BioWorld MedTech briefs for May 28, 2025. Boston Scientific Corp. reported the latest setback in its transcatheter aortic valve replacement (TAVR) aspirations with the news that it is officially... Pfizer Inc. is paying $1.25 billion up front and up to $4.8 billion in milestone payments to gain global, ex-China rights to SSGJ-707, a PD-1/VEGF bispecific... BioWorld Asia briefs for May 27, 2025
-
1 week ago | 
bioworld.com | Nuala Moran
Home » Glycoera raises a $130M series B to advance GE-8820 BioWorld briefs for May 28, 2025. BioWorld MedTech briefs for May 27, 2025. A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company... Salvia Bioelectronics BV raised $60 million in a series B financing round for its minimally invasive implantable neuromodulation device, Mysalvia therapy, which...
-
1 week ago | 
bioworld.com | Nuala Moran
Prothena sinks on phase III miss in amyloidosisHistory has repeated itself for Prothena Corp. plc, which has reported a second phase III miss for birtamimab in the treatment of light chain amyloidosis. Announcing the trial failure, the Dublin-based company said it is planning “a substantial reduction” of its organization. BioWorld Clinical Neurology/psychiatric Europe U.S.
